Han-Sin Jeong1, Hyunah Lee, Yejeung Ko, Young-Ik Son. 1. Department of Otorhinolaryngology-Head and Neck Surgery, Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Dendritic cells (DCs) can effectively mediate the prevention and regression of a variety of solid tumors. However, not much has been determined about their efficacy for the prevention of squamous cell carcinoma (SCC), partly because there are no known tumor-specific antigens or low immunogenicity for this tumor. The authors aimed to determine the preventive effect of DC-based immunotherapy in a SCC animal model. METHODS: Bone marrow derived DCs of C3H/He mice were pulsed with ultraviolet-B-irradiated apoptotic SCCVII cells, which are known as a poorly immunogenic SCC cell line. After the animals were vaccinated with these DCs, a tumorigenic dosage of SCCVII cells was subcutaneously injected and the tumor growth assessed. RESULTS: Animals pretreated with apoptotic SCCVII cell-pulsed DCs showed tumor extinction within 2 weeks after forming a small tumor, or there was no tumor formation at all, as seen in 81% of the mice; in the remaining 19% of the mice, tumor growth was significantly retarded compared with the control groups (P=.0029). The SCCVII cell-specific T-cell response was observed in the immunized mice. CONCLUSION: The adoptive transfer of DCs primed with apoptotic tumor cells can hopefully serve as an effective preventive vaccine, even in poorly immunogenic SCC.
BACKGROUND: Dendritic cells (DCs) can effectively mediate the prevention and regression of a variety of solid tumors. However, not much has been determined about their efficacy for the prevention of squamous cell carcinoma (SCC), partly because there are no known tumor-specific antigens or low immunogenicity for this tumor. The authors aimed to determine the preventive effect of DC-based immunotherapy in a SCC animal model. METHODS: Bone marrow derived DCs of C3H/He mice were pulsed with ultraviolet-B-irradiated apoptotic SCCVII cells, which are known as a poorly immunogenic SCC cell line. After the animals were vaccinated with these DCs, a tumorigenic dosage of SCCVII cells was subcutaneously injected and the tumor growth assessed. RESULTS: Animals pretreated with apoptotic SCCVII cell-pulsed DCs showed tumor extinction within 2 weeks after forming a small tumor, or there was no tumor formation at all, as seen in 81% of the mice; in the remaining 19% of the mice, tumor growth was significantly retarded compared with the control groups (P=.0029). The SCCVII cell-specific T-cell response was observed in the immunized mice. CONCLUSION: The adoptive transfer of DCs primed with apoptotic tumor cells can hopefully serve as an effective preventive vaccine, even in poorly immunogenic SCC.
Authors: Mark J Bluth; Lisa C Zaba; Dariush Moussai; Mayte Suárez-Fariñas; Helen Kaporis; Linda Fan; Katherine C Pierson; Traci R White; Alexander Pitts-Kiefer; Judilyn Fuentes-Duculan; Emma Guttman-Yassky; James G Krueger; Michelle A Lowes; John A Carucci Journal: J Invest Dermatol Date: 2009-04-23 Impact factor: 8.551
Authors: Victoria M Leb-Reichl; Melanie Kienzl; Anna Kaufmann; Angelika Stoecklinger; Birgit Tockner; Sophie Kitzmueller; Nadja Zaborsky; Markus Steiner; Gabriele Brachtl; Lisa Trattner; Patrick Kreideweiss; Christian Reinsch; Steffen Panzner; Richard Greil; Dirk Strunk; Johann W Bauer; Iris K Gratz; Christina Guttmann-Gruber; Josefina Piñón Hofbauer Journal: J Immunother Cancer Date: 2021-10 Impact factor: 13.751